Abstract:BACKGROUND:Propofol is commonly used for procedural sedation but may increase side effects in a dose-dependent manner. Remimazolam, an ultrashort-acting benzodiazepine, has been approved for procedural sedation but may delay awakening. This study tested the hypothesis that remimazolam as a supplement reduces effect-site propofol concentration (Ceprop) required to suppress response to cervical dilation in patients undergoing hysteroscopy.METHODS:One hundred and fifty patients who were scheduled for hysteroscopy were randomized to receive 0, 0.05, 0.1, 0.15, or 0.2 mg·kg-1 intravenous remimazolam, followed by a bolus of sufentanil 0.15 μg⋅kg-1, and a target-controlled propofol infusion. The initial target Ceprop was 3.5 μg·mL-1 and was increased or decreased in subsequent patients by steps of 0.5 μg·mL-1 according to whether there was loss of response to cervical dilation in the previous patient. We used up-down sequential analysis to determine values of Ceprop that suppressed response to cervical dilation in 50% of patients (EC50).RESULTS:The EC50 of propofol for suppressing response to cervical dilation was lower in patients given 0.1 mg·kg-1 (2.08 [95% confidence interval, CI, 1.88-2.28] μg·mL-1), 0.15 mg⋅kg-1 (1.83 [1.56-2.10] μg·mL-1), and 0.2 mg⋅kg-1 (1.43 [1.27-1.58] μg·mL-1) remimazolam than those given 0 mg⋅kg-1 (3.67 [3.49-3.86] μg·mL-1) or 0.05 mg⋅kg-1 (3.47 [3.28-3.67] μg·mL-1) remimazolam (all were P < .005). Remimazolam at doses of 0.1, 0.15, and 0.2 mg·kg-1 decreased EC50 of propofol by 43.3% (95% CI, 41.3%-45.5%), 50.3% (48.0%-52.8%), and 61.2% (58.7%-63.8%), respectively, from baseline (remimazolam 0 mg⋅kg-1). Propofol consumption was lower in patients given 0.1 mg⋅kg-1 (4.15 [3.51-5.44] mg·kg-1), 0.15 mg⋅kg-1 (3.54 [3.16-4.46] mg·kg-1), and 0.2 mg⋅kg-1 (2.74 [1.73-4.01] mg·kg-1) remimazolam than those given 0 mg⋅kg-1 (6.09 [4.99-7.35] mg·kg-1) remimazolam (all were P < .005). Time to anesthesia emergence did not differ significantly among the 5 groups.CONCLUSIONS:For women undergoing hysteroscopic procedures, remimazolam at doses from 0.1 to 0.2 mg·kg-1 reduced the EC50 of propofol inhibiting response to cervical dilation and the total propofol requirement. Whether the combination could improve perioperative outcomes deserves further investigation.

Influence of Remifentanil on Cp50 of Propofol Given by Target-Controlled Fusion for Loss of Consciousness

Propofol EC50 for Inducing Loss of Consciousness in Patients under Combined Epidural-General Anesthesia or General Anesthesia Alone: a Randomized Double-Blind Study

Dose-response Relationship of Remifentanil Inhibiting Responses to Endotracheal Intubation when Combined with Propofol in Severely Preeclamptic Patients Undergoing Caesarean Section

Effect of Remimazolam Supplementation on Propofol Requirements During Hysteroscopy: A Double-Blind, Dose-Response Study.

Effect of Different Target Plasma Concentrations of Remifentanil on Sedative Effect of Propofol

Target-controlled Infusion of Propofol Combined with Remifentanil or Fentanyl: a Comparison of Anesthetic Depth

Effect of Remifentanil on Propofol Pharmacokinetics with Target Controlled Infusion in Elderly Patients

Pharmacodynamics of propofol-remifentanil target-controlled infusion in elderly patients

Propofol Ec50 for Inducing Loss of Consciousness is Lower in the Luteal Phase of the Menstrual Cycle

Target-controlled Infusions of Remifentanil and Propofol During Thoracic Surgery

Effects on BIS of propofol-remifentanil target-controlled infusion in elderly patients

Clinical study of propofol with different concentration of fentanyl by target- controlled infusion

A comparison between target-controlled and manually controlled propofol infusions in patients undergoing routine surgical procedures.

Target-controlled Infusions of Remifentanil and Propofol During Laparoscopic Cholecystectomy

[Target-Controlled Infusions of Remifentanil and Propofol in Elderly Patients].

[Target-controlled infusion of remifentanil and propofol during operation with suspension laryngoscopy].

Up-and-down Sequential Method in Determining Median Effective Effect-Site Concentration (EC50) of Remifentanil Required for Inhibiting Intubation-Induced Hemodynamic Responses in Patients with Parkinson's Disease During Target-Controlled Infusion of Propofol

Pharmacodynamics interaction between propofol and remifentanil under different harmful stimulations analyzed by response surface methodology

C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial.

The Accuracy of Target-Controlled Infusion of Propofol in Chinese

A randomized comparison of target-controlled infusion of remifentanil and propofol with desflurane and fentanyl for laryngeal surgery